CytomX Therapeutics reported a patient death event to the FDA on August 15, 2025. Sean McCarthy serves as the CEO and chair.
3 reports, 2 independent
Updated Aug 15
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
CytomX Therapeutics reported a patient death event to the FDA on August 15, 2025. Sean McCarthy serves as the CEO and chair.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
CytomX Therapeutics (United States)
company in South San Francisco, United States
Nothing else this week.
- FDA
Coverage
Newest first; wire copies grouped- Clinical Trials ArenaCytomX to continue Phase I ADC trial despite patient death Despite a patient death occurring in its Phase I trial on investigative antibody-drug conjugate (ADC) CX-2051, CytomX Therapeutics will cont
- GlobeNewswireCytomX Therapeutics Provides Update on CX-2051 Phase 1 Study - The CTMX-2051-101 study has enrolled 73 colorectal cancer patients to-date, aligned with the Company’s goal of providing a Phase 1 data
- GlobeNewswireCytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update - May 12, 2025 announcement of positive interim data from ongoing Phase 1 study of CX-2051 (EpCAM Anti